

Karyopharm Therapeutics Inc.  
Form 4  
December 10, 2015

**FORM 4** UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

OMB APPROVAL  
OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Mirza Mansoor Raza

2. Issuer Name and Ticker or Trading Symbol  
Karyopharm Therapeutics Inc.  
[KPTI]

5. Relationship of Reporting Person(s) to Issuer  
  
(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
12/08/2015

Director  10% Owner  
 Officer (give title below)  Other (specify below)

C/O KARYOPHARM  
THERAPEUTICS INC., 85 WELLS  
AVENUE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

NEWTON, MA 02459

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) |       |                 | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|-------|-----------------|---|--|-----------------------------------|
|                                 |                                      |  |                                | Code  | V     | Amount or Price |   |  |                                   |
| Common Stock                    | 12/08/2015                           |  | M                              |   | 2,556 | A \$ 0.033      | 6,818   | D  |                                   |
| Common Stock                    | 12/08/2015                           |  | S                              |   | 2,556 | D \$ 15.0091    | 4,262   | D  |                                   |
| Common Stock                    | 12/08/2015                           |  | M                              |   | 6,061 | A \$ 0.033      | 10,323  | D  |                                   |
| Common Stock                    | 12/08/2015                           |  | S                              |   | 6,061 | D \$ 15.0091    | 4,262   | D  |                                   |
|                                 | 12/08/2015                           |  | M                              |   | 2,121 | A \$ 0.264      | 6,383   | D  |                                   |

Edgar Filing: Karyopharm Therapeutics Inc. - Form 4

Common  
Stock

Common Stock 12/08/2015 S 6,383 D \$ 15.0091 0 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock Option (Right to Buy)                | \$ 0.033   | 12/08/2015                           |  | M                              | 2,556   | <u>(1)</u> 11/04/2020                                    | Common Stock  | 2,556                         |
| Stock Option (Right to Buy)                | \$ 0.033   | 12/08/2015                           |  | M                              | 6,061   | <u>(2)</u> 01/20/2021                                    | Common Stock  | 6,061                         |
| Stock Option (Right to Buy)                | \$ 0.264   | 12/08/2015                           |  | M                              | 2,121   | <u>(3)</u> 12/13/2021                                    | Common Stock  | 2,121                         |

## Reporting Owners

**Reporting Owner Name / Address**

**Relationships**

Director 10% Owner Officer Other

Mirza Mansoor Raza  
C/O KARYOPHARM THERAPEUTICS INC.  
85 WELLS AVENUE

X

NEWTON, MA 02459

## Signatures

/s/ Christopher B. Primiano, Attorney-in-Fact for Mansoor Raza  
Mirza

12/10/2015

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option, representing a right to purchase a total of 9,091 shares, vested as to 25% of the shares on November 5, 2011, and the remaining 75% of the shares vested in 36 equal monthly installments thereafter.
- (2) This option, representing a right to purchase a total of 6,061 shares, vested as to 25% of the shares on October 22, 2011, and the remaining 75% of the shares vested in 36 equal monthly installments thereafter.
- (3) This option, representing a right to purchase a total of 8,220 shares, vested as to 25% of the shares on December 12, 2012, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.